Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

ABBV – AbbVie Inc.

Float Short %

1.12

Margin Of Safety %

-14

Put/Call OI Ratio

0.93

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

1.53

Price

224.96

Target Price

254.88

Analyst Recom

1.81

Performance Q

-3.87

Upside

-76.8%

Beta

0.33

Ticker: ABBV




17 items of 1

DateSymbolLatestP/C OIP/C VolTotal OI
2026-01-23ABBV219.260.880.48206856
2026-01-26ABBV220.680.910.47201556
2026-01-27ABBV223.920.890.50207119
2026-01-28ABBV218.510.880.86209884
2026-01-29ABBV220.440.890.83211867
2026-01-30ABBV222.990.890.46213430
2026-02-02ABBV225.650.920.55203216
2026-02-04ABBV217.020.920.67217253
2026-02-05ABBV217.230.920.74223032
2026-02-06ABBV223.370.920.55229560
2026-02-09ABBV223.20.920.38218565
2026-02-10ABBV222.40.890.81226678
2026-02-11ABBV220.860.890.42229363
2026-02-12ABBV227.730.890.75231802
2026-02-13ABBV231.560.900.50235840
2026-02-18ABBV228.650.911.49236685
2026-02-19ABBV224.40.930.39240930
DateSymbolLatestP/C OIP/C VolTotal OI
17 items Current Page1 of 1




17 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2026-01-23ABBV219.2643.627127.910.64
2026-01-26ABBV220.6639.627158.310.64
2026-01-27ABBV223.8939.327368.610.64
2026-01-28ABBV218.9322.126377.410.64
2026-01-29ABBV220.3822.127197.010.64
2026-01-30ABBV223.0522.927307.710.64
2026-02-02ABBV225.6622.927308.010.64
2026-02-03ABBV225.6622.927011.110.64
2026-02-04ABBV216.9722.925936.910.64
2026-02-05ABBV218.9726.027217.114.22
2026-02-06ABBV223.3526.027520.414.22
2026-02-09ABBV223.1623.026952.314.47
2026-02-10ABBV222.3822.726877.314.57
2026-02-12ABBV227.6422.727814.514.57
2026-02-18ABBV228.6422.726489.714.57
2026-02-19ABBV224.3922.726468.814.57
2026-02-20ABBV224.9622.1- 14.51
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
17 items Current Page1 of 1




20 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2026-01-23ABBV-3.380.221.12
2026-01-26ABBV-3.380.121.12
2026-01-27ABBV-3.050.121.12
2026-01-28ABBV-3.380.121.25
2026-01-29ABBV-3.380.121.25
2026-01-30ABBV-3.380.121.25
2026-02-02ABBV-3.380.211.25
2026-02-03ABBV-3.380.211.25
2026-02-04ABBV-3.380.211.25
2026-02-05ABBV-3.380.211.25
2026-02-06ABBV-3.380.211.25
2026-02-09ABBV-2.590.461.25
2026-02-10ABBV-2.590.461.25
2026-02-11ABBV-2.590.461.11
2026-02-12ABBV-2.590.461.11
2026-02-13ABBV-2.590.461.11
2026-02-17ABBV0.001.321.11
2026-02-18ABBV0.001.321.11
2026-02-19ABBV0.001.321.11
2026-02-20ABBV0.001.321.12
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
20 items Current Page1 of 1

Last Quarter Act. EPS

Avg. EPS Est. Current Quarter

3

Avg. EPS Est. Next Quarter

3.77

Insider Transactions

Institutional Transactions

1.32

Beta

0.33

Average Sales Estimate Current Quarter

14715

Average Sales Estimate Next Quarter

16815

Fair Value

192.91

Quality Score

61

Growth Score

75

Sentiment Score

71

Actual DrawDown %

8.1

Max Drawdown 5-Year %

-21.9

Target Price

254.88

P/E

94.97

Forward P/E

13.93

PEG

0.66

P/S

6.5

P/B

P/Free Cash Flow

20.19

EPS

2.37

Average EPS Est. Cur. Y​

14.51

EPS Next Y. (Est.)

16.04

Target Price Estimates Raised

1

Target Price Estimates Lowered

Profit Margin

6.86

Relative Volume

1.05

Return on Equity vs Sector %

-117.9

Return on Equity vs Industry %

-126.3

EPS 1 7Days Diff

-0.1

EPS 1 30Days Diff

0.27

EBIT Estimation

AbbVie Inc.
Sector: Healthcare
Industry: Drug Manufacturers - General
Employees:
AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacture, commercialization, and sale of medicines and therapies worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, generalized pustular psoriasis, and pyoderma gangrenosum; Skyrizi to treat autoimmune diseases, erythrodermic psoriasis, generalized pustular psoriasis, and palmoplantar pustulosis; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta/Venclyxto to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic to treat neurologic diseases; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duopa and Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; and Qulipta for episodic and chronic migraine, as well as other neuroscience products. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; and Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation. AbbVie Inc. has strategic partnership with OSE Immunotherapeutics. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
stock quote shares ABBV – AbbVie Inc. Stock Price stock today
news today ABBV – AbbVie Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch ABBV – AbbVie Inc. yahoo finance google finance
stock history ABBV – AbbVie Inc. invest stock market
stock prices ABBV premarket after hours
ticker ABBV fair value insiders trading